BiotechTube
Changchun High-Tech Industry

Changchun High-Tech Industry

000661.SZPre-clinical
5,000-10,000 employeeschangchun-high-tech.com

Changchun High-Tech is a prominent, revenue-generating biopharmaceutical enterprise in China, primarily known for its vaccine business. Its strategic position is anchored by its controlling stake in Changchun BCHT Biotechnology, a critical supplier of the Varicella vaccine in the domestic market. The company leverages this established commercial foundation to invest in and develop a broader pipeline of biological products, including monoclonal antibodies and other innovative therapeutics. As a publicly listed entity, it operates with a diversified business model that also includes investments in real estate and other industries.

Market Cap
$5.0B
-16.3% period
Pipeline
—
Patents
—
Publications
6
indexed

000661.SZ · Stock Price

USD 83.7616.34 (-16.32%)

Historical price data

AI Company Overview

Changchun High-Tech is a prominent, revenue-generating biopharmaceutical enterprise in China, primarily known for its vaccine business. Its strategic position is anchored by its controlling stake in Changchun BCHT Biotechnology, a critical supplier of the Varicella vaccine in the domestic market. The company leverages this established commercial foundation to invest in and develop a broader pipeline of biological products, including monoclonal antibodies and other innovative therapeutics. As a publicly listed entity, it operates with a diversified business model that also includes investments in real estate and other industries.

Infectious DiseaseOncologyEndocrinologyAutoimmune DiseasesInfertility

Technology Platform

Integrated bioprocess development and large-scale GMP manufacturing for viral vaccines, recombinant proteins, and monoclonal antibodies, with core expertise in cell culture and lyophilization.

Opportunities

Significant opportunities exist in the expanding Chinese biosimilars market and the continued high demand for pediatric and routine vaccines.
The company can leverage its strong cash flow and manufacturing base to in-license or co-develop innovative assets, transitioning towards a more innovative biopharma model.

Risk Factors

Major risks include severe pricing pressure from China's Volume-Based Procurement (VBP) policy for biosimilars, over-reliance on revenue from a single vaccine product (Varicella), and intense competition across all its business segments.
Regulatory changes pose a constant threat.

Competitive Landscape

Faces intense competition from domestic giants like Walvax and Sinovac in vaccines, and from a crowded field of biosimilar developers such as Innovent and Henlius. Differentiation is based on its established vaccine market position, integrated manufacturing, and domestic commercial footprint, but it lacks a clear innovative pipeline advantage over more R&D-focused peers.